Brian W. Loggie, MD
Brian W. Loggie, MD

Brian W. Loggie, MD

Professor
School of Medicine

Expertise/Specializations

  • Surgical Oncology

Academic Appointments

Department

  • Surgery

Position

  • Professor

Education

  • Loyola College,1971-1973
  • McGill University,Premed,1973-1974
  • McGill University,M.D.,7/74-6/79
  • Montreal General Hospital Internship, Department of Surgery Resident, Department of Surgery Montreal, Canada 1979-1980 1980-1986
  • McGill University Graduate Studies, Department of Experimental Surgery Montreal, Canada 1982-1986
  • University of Illinois at Chicago Clinical and Research Fellowship in Surgical Oncology Chicago, Illinois 1986-1988

Certifications

 Licensed Physician
State of Nebraska, License 22172           2002-Present

Licentiate of Medical Council of Canada (LMCC)  July 19, 1982
  
License to Practice Medicine in Quebec
Includes French CertificationJuly 12, 1982
  
Licensed Physician and Surgeon
State of IllinoisJuly 1986
   
Licensed Physician
State of North Carolina 1988-Present 
  
National Cancer Institute Investigator’s LicenseNovember 1990
  
Licensed Physician
State of Texas, License K9334   2000-Present 
 
- General Surgery (Canadian, American Boards) - SSO Approved Surgical Oncology Fellowship 1986-88

Royal College of Physicians and Surgeons of Canada
Specialist Certificate in General SurgeryNovember 1986  
   
Diplomate of the American Board of SurgeryDecember 1990 
   
Certificate of Training in Surgical Oncology
University of Illinois School of Medicine, Department of SurgeryJune 1998  
   
Recertification
American Board of Surgery, General SurgeryDecember 2011  
   
Private Pilot Certification
ASELMarch 6, 2004
  
 

Publications and Presentations

Books


  • Shetty S, Loggie BW. Pseudomyxoma peritonei as a special subset of peritoneal carcinomatosis. In: Advances in the Management of Peritoneal Carcinomatosis. Rose PG, Knight J (Eds). Future Medicine, London, UK. , Future Medicine, 2013

Articles

  • Smith  Sean, Kirkpatrick  Daniel, Thomas Peter, Loggie Brian.  Current Perspectives on Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer.   Gastrointestinal Cancer:  Targets and Therapy, DovePress.  , Gastrointestinal Cancer: Targets and Therapy, 20-30, 2017
  • Natarajan, B., Shetty, S., Loggie B.W., Impact of tumor aneuploidy in mucinous appendiceal neoplasms, American Surgeon, 2017
  • Kuracha Murali R, Thomas Peter, Loggie Brian W, Govindarajan Venkatesh. Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment., Cancer Medicine, 2016
  • Sean Judge, Peter Thomas, V. Govindarajan, Poonan Sharma, Brian Loggie: ”Malignant Peritoneal mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment”, Gastrointestinal Oncology Annals of Surgical Oncology, 1-5, 2015
  • Loggie, Brian; Thomas, Peter: Gastrointestinal Cancers with Peritoneal Carcinomatosis: Surgery and Hyperthermic Intraperitoneal Chemotherapy., Oncology, 29 (7) , 515-521, 2015
  • Malesker, M., Bruckner, A., Loggie, B., & Hilleman, D. (2015). IV Acetaminophen: Assessment of Medication Utilization Evaluation Data in Peri-operative Pain Management, Journal of Surgery, 10(4), 227-228, 2014
  • Lohani, Kush, Shetty, Shreya, Sharma, Poonam, Govindarajan,Venkatesh, Thomas, Peter, Loggie, Brian. Pseudomyxoma Peritonei: Inflammatory Responses in the Peritoneal Microenvironment, Annals of Surgical Oncology, 21, 1441-1447, 2014
  • Shreya J. Shetty MBBS1, Lokesh Bathla MD2, Venkatesh Govindarajan, Ph.D.1 Peter Thomas, Ph.D1. Brian W. Loggie MD1.  Comparison of Visceral Sparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Mitomycin or Carboplatin for Diffuse Malignant Peritoneal Mesothelioma. , American Surgeon, 80, 2014
  • Levine EA, Stewart JHt, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients., J Am Coll Surg, 2013
  • Foster, J ,Gupta, P,Carreau, J,Grotz, T, Blas, J,Gatalica, Z, Nath, S, Loggie, B. Right hemicolectomy is not routinely indicated in pseudomyxoma peritonei., American Surgeon, 78(2), 171-177, 2012
  • Xintian Zhang, Peng Shen, Megan Colemen, Wei Zou, Brian W. Loggie, Leia M. Smith and Zhaoyi Wang. Caveolin-1 Down-regulation Activates Estrogen Receptor Alpha Expression and Leads to 17-B-estradiol-stimulated Mammary Tumorigenesis, Anticancer Res., 25, 369-376, 2005
  • Hall J, B Loggie, P Shen, S Beamer, LD Case, R McQuellon, K Geisinger and E Levine. Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Advanced Gastric Cancer., Journal of Gastrointestinal Surgery, 8(4), 454-463, 2004
  • Shen P, J Hawksworth, J Lovato, B Loggie, KR Geisinger, R Fleming and EA Levine. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy with Mitomycin C for Peritoneal Carcinomatosis from Non-Appendiceal Colorectal Carcinoma., Annals of Surgical Oncology, 11(2), 178=186, 2004
  • Shen P, EA Levine and B Loggie. Peritoneal Carcinomatosis: What Can We Do About It?, J Clinical Oncology, Jan 1:22(1), 202, 2004
  • McQuellon RP, B Loggie, AB Lehman, GB Russell, RA Fleming, P Shen, and EA Levine. Long-Term Survivorship and Quality of Life Following Intraperitoneal Hyperthermic chemotherapy ofor peritoneal Carcinomatosis., Annals of Surgical Oncology, 10(2), 155-162, 2003
  • Zhang TF, SQ Yu, B Loggie and ZY Wang. Inducible Expression of RbAp46 Activates c-Jun NH2-Terminal kinase-Dependent Apoptosis and Suppresses Progressive Growth of Tumor Xenografts in Nude Mice., Anticancer Res., 23, 4621-4628, 2003
  • Shen P, EA Levine, J Hall, D Case, G Russell, RA Fleming, RP McQuellon, KR Geisinger, B Loggie. Factors Predicting Survival Following Intraperitoneal Hyperthermic Chemotherapy with Mitomycin C after Cytoreductie Surgery for Patients with Peritoneal Carcinomatosis., Archives of Surgery, 2003, 138, 26-33, 2003
  • Shen P., E. Levine, J. Hall, D. Case, G. Russell, R. Fleming, R. McQuellon, K. Geisinger, B. Loggie. Factors and Quality of Life Following Intrperitoneal Hyperthermic Chemotherapy with Mitomycin C After Cytoreductive Surgery for Patients with Peritoneal Carcinomatosis., Archives of Surgery, 2003; 138:, 26-33, 2003
  • Shen P., A. Hoffman, R. Howerton, B. Loggie. Cryosurgery of Close or Positive Margins After Hepatic Resection for Primary and Metastatic Hepatobiliary Malignancies., American Surgeon, 2003; 68:, 695-703, 2003
  • Fleming R., B. Loggie, J. Drees, etal. Clinical Significance of NAD(P)H: Quinone Oxidoreductase 1 Polymorphism in Patients with Disseminated Peritoneal Cancer Receiving Intraperitoneal Hyperthermic Chemotherapy with Mitomyciin C., Pharmacogenetics, 2002; 12:, 31-7, 2002
  • Gao X., B. Loggie, Z. Nawaz. The Roles of Sex Steroid Receptor Coregulators in Cancer., Molecular Cancer, Nov. 2002:, 1-7, 2002
  • Shen P., A. Hoffman, R. Howerton, B. Loggie. Cryosurgery of close or positive margins after hpatic resection for primary and metastatic hepatobiliary malignancies., American Surgeon, 68, 695-703, 2002
  • Fleming R., B.Loggie, J.Drees, et al. Clinical Significance of a NAD(P)H: Quinone Oxidoreductase 1 Polymorphism in Patients with Disseminated Peritoneal Cancer Receiving Intraperitoneal Hyperthermic Chemotherapy with Mitomycin C., Pharmacoeconomics, 12, 31-37, 2002
  • Evans H., D.Krag, C.Teates, J.Patterson, S.Meijer, S.Harlow, K.Tanabe, B.Loggie, P.Whitworth, R.Kusminsky, N.Carp, M.Gadd, C.Slingluff. Lymphoscintigraphy and Sentinel Node Biopsy Accurately Stage Melanoma in Patients Presenting After Wide Excision. Annals of Surgical Oncology 2003: in press

Publications

  • Loggie, B., Ye Y., Srinivasan, S., Nawaz, Z. Inhibition of Mucin 1 Production in Colon Cancer presented at the 58th Anuual Cancer Symposium by the Society of Surgical Oncology., Not Applicable, 2005
  • Burjonrappa SC, Z Nawaz, X Ha, S Poonam, G Zoran and BW Loggie. Mucin Expression in Normal, Dysplastic and Malignant Esophagus., Society of University Surgeons, 2005
  • Hundley JC, P Shen, BW Loggie, GB Russell, RF Bradley, KR Geisinger and EA Levine. Appendiceal Neoplasms with Pseudomyxoma Peritonei: Outcome in 100 Patients Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy. 2005, Society of Surgical Oncology, 2005
  • Loggie B, EL Silva, Z Gatalica, GA El-Ella. Inhibition of Mucin2 Production: Implications for Treament of Pseudomyxoma Peritonei., Annals of Surgical Oncology, Abstract Book, 566, 2004
  • Gatalica Z, J Knezetic, J Choquette, L Linder-Stephenson, B Loggie and HT Lynch. Microsatellite Instability in Patients with Peritoneal Mucinous Carcinomatosis., J Molec Diag, 6(2), 152, 2004
  • Fleming R., B.Loggie, J.Drees, et al. Clinical Significance of a NAD(P)H: Quinone Oxidoreductase 1 Polymorphism in Patients with Disseminated Peritoneal Cancer Receiving Intraperitoneal Hyperthermic Chemotherapy with Mitomycin C. Submitted to Pharmacogenetics.

Presentations

  • Oral Meeting Presentation: Dr. Peter Thomas presenting: Carcinoembryonic Antigen (CEA) : A Potential Mediator of inflammation in Pseudomyxoma Peritonei. Peter Thomas, Murali Kuracha, Brian Loggie and Venkatesh Govindarajan. 25th Annual International CEA Symposium, Washington, DC, 2015
  • Sean Judge, MS, Shreya Shetty, MBBS, Peter Thomas, PhD, Venkatesh Govindarajan, PhD, Poonam Sharma, MD, Brian Loggie, MD. Factors Associated with Survival in Patients with Pseudomyxoma Peritonei: Influence of Sigent Ring Cells. American College of Surgeons 2014 Clinical Congress, San Fransicso, CA, 2014
  • Nomograms to predict prognosis in pseudomyxoma peritonei: A  Peritoneal Surface Oncology Group International (PSOGI) multicenter study. 2014 ASCO Annual Meeting,  Chicago, Illinois, 2014
  • “Ninth International Symposium on Regional Cancer Therapies”
    Moderator.  Steamboat Springs, Colorado, 2014
  • “Management of Patients with Peritoneal Surface Malignancies”
    Alegent Creighton Health Cancer Center
    Bergan Mercy Medical Center.  Omaha, Nebraska

     , 2013
  •  “Pseudomyxoma Peritonei and Peritoneal Carcinomatosis.”
    Department of Pathology
    Creighton University School of Medicine
    Grand RoundsOmaha, Nebraska
     , 2013
  • Lohani, K., Shett, S., Judge, S., Govindarajan, V., Thomas, P., Loggie, B. Microenvironment and Cytokines in Pseudomyxoma Peritonei. ASCO GI Symposium, San Francisco, CA, 2013
  • “Proposed New PMP Classification system: Implications for Therapy.”
    8th World Congress on Surface MalignanciesBerlin, Germany
     , 2012
  • Loggie, B. Hyperthermic Intraperitoneal Chemotherapy in Non-gynecological Cancers. International Symposium on Pertitoneal Therapy for Ovarian Cancer at University of Louisville in Louisville, KY., 2005
  • Burjonrappa SC, Z Nawaz, X Ha, S Poonam, G Zoran, BW Loggie. Mucin Expression in Normal, Dysplastic and Malignant Esophagus. Society of University Surgeons., 2005
  • Loggie B. Innovations In Surgical Oncology: Technical Aspects of Debulking and Peritoneal Perfusion. University of Pittsburgh School of Medicine. Pittsburgh, Pennsylvania, 2004
  • Loggie B. Inhibition of Mucin2 Production: Implications for Treatment of Pseudomyxoma Pertonei. Grand Rounds. St. Luke's-Roosevelt Hospital. New York City, New York, 2004
  • Loggie BW, Nawaz Z, Gatalica Z, Silva E and El-Ella GA. Inhibition of Mucin2 Production: Implications for Treatment of Pseudomyxoma Peritonei. The Society of Surgical Oncology's Cancer Symposium; New York, NY, March 18-21, 2004., 2004
  • Loggie BW, Nawaz Z, Gatalica Z, Silva E, and El-Ella GA. Implications for Treatment of Pseudomyxoma Pertonei; ICACT: 15th International Congress on Anti-Cancer Treatment; Session on Regional Tumor Treatment. Paris, France, Europe Feb. 9th, 2004, 2004
  • Loggie BW, Nawaz Z, Gatalica Z, Silva E and El-Ella GA. Inhibition of Mucin2 Production: Implications for Treatment of Pseudomyxoma Pertonei. ASCO Gastrointestinal Cancers Symposium; San Francisco, January 22-24, 2004, 2004
  • Meet the Professor, The 56th Annual Cancer Symposium, Society of Surgical Oncology, Los Angeles, California., 2003
  • Care of the Patient Requiring Surgical Intervention For the Treatment of Peritoneal Carcinomatosis, 2002

Research and Scholarship

Research and Scholarship Interests

  • Surgical Oncology Peritoneal carcinomatosis, appendix neoplasms, pseudomyxoma peritonei, mucinous colorectal cancers, malignant peritoneal mesothelioma

Current Research Projects

  • Same.

Awards and Honors

  • Provisonal-EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AND METHODS OF USE (Patent No: 60/881070), 2007
  • NOVEL USE OF A CANCER DRUG (Patent No: PCT/US2005/002111), 2005
  • POLYNUCLEOTIDES FOR INHIBITION OF POLYPEPTIDE EXPRESSION AND METHODS OF USE (Patent No: pct/us2004/038116), 2004
  • INHIBITION OF MUCIN 2 PRODUCTION: IMPLICAIONS FOR TREATMENT OF PSEUDOMOYXOMA PERITONEI (Patent No: 60/538,920), 2004
  • INHIBITION OF MUCIN 2 PRODUCTION: IMPLICATIONS FRO TREATMENT OF PSEUDOMYXOMA PERITONEI (Patent No: 60/538,740), 2004